Compare IOVA & TRIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOVA | TRIP |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | 975 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2008 | 2011 |
| Metric | IOVA | TRIP |
|---|---|---|
| Price | $3.42 | $11.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 13 |
| Target Price | $9.00 | ★ $14.58 |
| AVG Volume (30 Days) | ★ 13.7M | 3.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.84 | ★ 675.00 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $1,556,000,000.00 |
| Revenue This Year | $47.74 | $3.33 |
| Revenue Next Year | $40.31 | $5.12 |
| P/E Ratio | ★ N/A | $34.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.64 | $9.01 |
| 52 Week High | $5.63 | $20.16 |
| Indicator | IOVA | TRIP |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 54.27 |
| Support Level | $2.05 | $9.36 |
| Resistance Level | $4.33 | $15.37 |
| Average True Range (ATR) | 0.30 | 0.49 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 22.44 | 41.32 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025, and TheFork, its dining brand, represented 12% of sales.